Immunicom Overview
- Year Founded
-
2013
- Status
-
Private
- Employees
-
27
- Latest Deal Type
-
Grant
- Latest Deal Amount
-
$2M
- Investors
-
4
Immunicom General Information
Description
Developer of a therapeutic device intended for treating cancer, inflammatory, and autoimmune diseases. The company's revolutionary blood-filtering device specializes in effectively treating a wide variety of cancer types including those that have not responded to other treatment strategies including other drug and biological-based immunotherapy options with possibly fewer side effects, enabling physicians to directly attack cancer while enhancing the effects of other cancer treatments which may be used concurrently.
Contact Information
Website
www.immunicom.comCorporate Office
- 6048 Cornerstone Court West
- Suite D
- San Diego, CA 92121
- United States
Corporate Office
- 6048 Cornerstone Court West
- Suite D
- San Diego, CA 92121
- United States
Immunicom Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 5. Grant | 08-Jun-2022 | $2M | Completed | Clinical Trials - General | ||
| 4. Debt - PPP | 10-Apr-2020 | Completed | Clinical Trials - General | |||
| 3. Later Stage VC (Series B) | 01-Oct-2019 | Completed | Clinical Trials - General | |||
| 2. Early Stage VC (Series A) | 01-Nov-2015 | $5.5M | $12.2M | Completed | Startup | |
| 1. Early Stage VC | $6.65M | $6.65M | Completed | Startup |
Immunicom Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate ($) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series B | ||||||||
| Series A |
Immunicom Comparisons
Industry
Financing
Details
Immunicom Competitors (5)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Biosceptre | Venture Capital-Backed | Cambridge, United Kingdom | ||||
| Vertex Pharmaceuticals | Formerly VC-backed | Boston, MA | ||||
| Regenxbio | Formerly VC-backed | Rockville, MD | ||||
| Arrowhead Pharmaceuticals | Corporation | Pasadena, CA | ||||
| Kite Pharma | Formerly VC-backed | Santa Monica, CA |
Immunicom Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Immunicom Patents
Immunicom Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20220409795-A1 | Modified tnf as a capture ligand | Active | 17-Jun-2021 | ||
| JP-2024525352-A | Modified tnf as a capture ligand | Pending | 17-Jun-2021 | ||
| EP-4355381-A1 | Modified tnf as a capture ligand | Pending | 17-Jun-2021 | ||
| AU-2022291929-A1 | Modified tnf as a capture ligand | Pending | 17-Jun-2021 | ||
| CA-3222835-A1 | Modified tnf as a capture ligand | Pending | 17-Jun-2021 | B01D15/3828 |
Immunicom Executive Team (10)
| Name | Title | Board Seat |
|---|---|---|
| Amir Jafri | Founder, Chief Executive Officer, President & Board Member | |
| Raju Chauhan | Chief Operating Officer | |
| Steven Josephs Ph.D | Director of Product Development & Chief Scientist | |
| Stephen Prince | Chief Commercial Officer | |
| Lawrence Florin | Chief Clinical Officer & Executive Vice President of Clinical Operations |
Immunicom Board Members (10)
| Name | Representing | Role | Since |
|---|---|---|---|
| Gary Pace Ph.D | Self | Board Member | |
| John Miller | Self | Board Member | |
| John Rompon JD | Self | Board Observer | |
| Michael Barrett | Self | Board Member | |
| Michael Lehman | Self | Board Member |
Immunicom Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Immunicom Investors (4)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| National Cancer Institute | Government | |||
| National Institutes of Health | Government | |||
| Zfounder | Venture Capital | Minority | ||
| Bootstrap Venture Partners | Venture Capital | Minority |
Immunicom FAQs
-
When was Immunicom founded?
Immunicom was founded in 2013.
-
Who is the founder of Immunicom?
Amir Jafri is the founder of Immunicom.
-
Who is the CEO of Immunicom?
Amir Jafri is the CEO of Immunicom.
-
Where is Immunicom headquartered?
Immunicom is headquartered in San Diego, CA.
-
What is the size of Immunicom?
Immunicom has 27 total employees.
-
What industry is Immunicom in?
Immunicom’s primary industry is Therapeutic Devices.
-
Is Immunicom a private or public company?
Immunicom is a Private company.
-
What is Immunicom’s current revenue?
The current revenue for Immunicom is .
-
How much funding has Immunicom raised over time?
Immunicom has raised $25M.
-
Who are Immunicom’s investors?
National Cancer Institute, National Institutes of Health, Zfounder, and Bootstrap Venture Partners have invested in Immunicom.
-
Who are Immunicom’s competitors?
Biosceptre, Vertex Pharmaceuticals, Regenxbio, Arrowhead Pharmaceuticals, and Kite Pharma are competitors of Immunicom.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
